Inhibitor

Study Design

ORR

mPFS

References

Capmatinib

NCT02414139 (GEOMETRY mono-1), N = 364 (phase II), Capmatinib monotherapy

68.8%

12.5 mo.

Wolf et al. 2020 [3]

Tepotinib

NCT02864992 (VISION), N = 152 (phase II), Tepotinib monotherapy

44.9%

8.5 mo.

Paik et al. 2020 [4]